|Bid||139.34 x 100|
|Ask||0.00 x 0|
|Day's Range||140.64 - 143.22|
|52 Week Range||92.35 - 143.22|
|PE Ratio (TTM)||52.72|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
On March 6, 2018, Abbott Laboratories (ABT) announced that it received FDA (US Food and Drug Administration) approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants. The trial included patients five years and under who had damaged, diseased, or malfunctioning heart valves. On March 6, 2018, ABT stock rose ~0.86%, whereas Medtronic (MDT), Boston Scientific (BSX), and Edwards Lifesciences (EW), which are the other major players in the structural heart device business, saw gains of ~0.83%, ~0.04%, and ~1.2%, respectively.
Edwards Lifesciences (EW) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $15.64 billion.
Edwards Lifesciences (EW) is a global leader in medical innovation for structural heart disease and critical care monitoring. Edwards Lifesciences’ product pipeline is focused on the repair or replacement of the mitral and tricuspid valves of the heart. Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating, while four analysts have given it a “hold” rating.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
BSX Stock Recovers after a Robust 4Q17: What's to Come? On February 1, 2018, Boston Scientific (BSX) announced its 4Q17 and 2017 earnings results. Boston Scientific’s 2017 performance was affected by a series of events within the company as well as macroeconomic developments such as the recall of its Lotus devices, the hurricanes and wildfires in the United States, and the US tax reform.
BSX Stock Recovers after a Robust 4Q17: What's to Come? On January 24, 2018, Boston Scientific (BSX) announced an investment deal, including an acquisition option, with Millipede, a California-based, privately-held company. The deal strengthens Boston Scientific’s position in the mitral valve therapy market for the treatment of MR (mitral regurgitation) patients.